Form 4 for NDRA ENDRA Life Sciences Inc.
Accepted 2023-05-03 00:00:00 ET · period of report 2023-05-02 · accession 0001209191-23-026925 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-03 | 2023-05-02 | NDRA | DIGIANDOMENICO ANTHONY | Dir | P - Purchase | $1.20 | +83.3K | 102.4K | +436% | +$100.0K |
| D | 2023-05-03 | 2023-05-02 | NDRA | DIGIANDOMENICO ANTHONY | Dir | P - Purchase | $0.01 | +41.7K | 41.7K | New | +$416.67 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-02 | P | A | 83,333 | $1.20 | 102,434 | D | — | — | (F1) Represents shares purchased in the Registrant's underwritten public offering that closed May 2, 2023 (the "Offering"). (F2) The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant in the Offering. |
| 2 | Derivative | Warrants | 2023-05-02 | P | A | 41,667 | $0.01 | 41,667 | D | $1.40 · 2023-05-02 to 2028-05-02 | 41,667 Common Stock | (F2) The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant in the Offering. |